Sugi Predict

Sugi Predict / Compounds / SCHEMBL2677477

SCHEMBL2677477

SCHEMBL2677477

CN(C)CCOc1ccc(C(=O)Nc2n[nH]c3c2CN(S(=O)(=O)c2cc(F)cc(F)c2)CC3)c(N)c1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 4/20 0.54
▸ HMOX1 P09601 4/20 0.37
▸ INSR P06213 1/20 0.37
▸ ALK Q9UM73 1/20 0.37
▸ LSS P48449 1/20 0.36
▸ USP9X Q93008 1/20 0.35
▸ EP300 Q09472 2/20 0.35
▸ CREBBP Q92793 2/20 0.35
▸ MET P08581 1/20 0.35
▸ LCK P06239 1/20 0.34
▸ KIT P10721 2/20 0.34
▸ FLT3 P36888 1/20 0.34
▸ CCNA2 P20248 2/20 0.34
▸ CDK2 P24941 2/20 0.34
▸ CCNA1 P78396 2/20 0.34
▸ AURKA O14965 1/20 0.34
▸ PAK4 O96013 1/20 0.33
▸ HRH3 Q9Y5N1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1897920 0.93 IGF1R (0.53) IGF1RHMOX1INSRALKEP300
SCHEMBL2677466 0.92 IGF1R (0.54) IGF1RHMOX1LSSUSP9XEP300
SCHEMBL2678543 0.88 IGF1R (0.60) IGF1RHMOX1INSRALKEP300
SCHEMBL1891706 0.87 IGF1R (0.51) IGF1RINSRALKLSSMET
SCHEMBL2679410 0.87 IGF1R (0.56) IGF1RHMOX1INSRALKEP300
SCHEMBL2678137 0.87 IGF1R (0.56) IGF1RHMOX1INSRALKEP300
SCHEMBL2679134 0.86 IGF1R (0.39) IGF1RCCNA2CDK2CCNA1PAK4
SCHEMBL1886685 0.86 IGF1R (0.69) IGF1RLSSUSP9XEP300CREBBP
SCHEMBL1887232 0.86 IGF1R (0.55) IGF1RINSRALKLSSUSP9X
SCHEMBL2453861 0.85 IGF1R (0.54) IGF1RHMOX1INSRALKEP300

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120932-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER Nerviano Medical Sciences S.r.l. (IT) 2009-11-25 — — EP claimed
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-22 — — US claimed
WO-2008074749-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2008-06-26 — — WO claimed
US-8173659-B2 Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-05-08 — — US disclosed
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-22 — — US disclosed
EP-1968976-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-09-17 — — EP disclosed
WO-2007068619-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors MAP3K3, MAP3K1, MAP3K19 IGF1R 760/4885HMOX1 3686/4885INSR 922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.